Oral Aβ Vaccine Using a Recombinant Adeno-Associated Virus Vector in an Alzheimer’s Disease Mouse Model

  • Takeshi Tabira
  • Hideo Hara
Conference paper
Part of the Advances in Behavioral Biology book series (ABBI, volume 57)


Amyloid Precursor Protein Amyloid Burden Amyloid Precursor Protein Mouse Tg2576 Amyloid Precursor Protein Transgenic Mouse Treat Tg2576 Mouse 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Selkoe DJ. Alzheimer’s disease: genes, proteins and therapies. Physiol Rev 2001;81:742–761.Google Scholar
  2. 2.
    Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173–177.PubMedCrossRefGoogle Scholar
  3. 3.
    Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000;6:916–919.PubMedCrossRefGoogle Scholar
  4. 4.
    Janus C, Pearson J, McLaurin J, et al. Ab peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer’s disease. Nature 2000;408:979–982.PubMedCrossRefGoogle Scholar
  5. 5.
    Morgan D, Diamond DM, Gottschall PE, et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature 2000;408:982–985.PubMedCrossRefGoogle Scholar
  6. 6.
    Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Ab42 immunization. Neurology 2003;61:46–54.PubMedGoogle Scholar
  7. 7.
    Nicoll JA, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat Med 2003;9:448–452.PubMedCrossRefGoogle Scholar
  8. 8.
    Ferrer I, Boada Rovira M, Sanchez Guerra ML, et al. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 2004;14:11–20.PubMedCrossRefGoogle Scholar
  9. 9.
    Masliah E, Hansen L, Adame A, et al. Aß vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005;64:129–131.PubMedGoogle Scholar
  10. 10.
    Hock C, Konietzlo U, Streffer JR, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003;38:547–554.PubMedCrossRefGoogle Scholar
  11. 11.
    Gilman S, Koller M, Black RS, et al. Clinical effects of Ab immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64:1553–1562.PubMedCrossRefGoogle Scholar
  12. 12.
    Hara H, Monsonego A, Yuasa K, et al. Development of a safe oral Abeta vaccine using recombinant adeno-associated virus vector for Alzheimer's disease. J Alzheim Dis 2004;6:483–488.Google Scholar
  13. 13.
    Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998;72:2224–2232.PubMedGoogle Scholar
  14. 14.
    Monsonego A, Zota V, Kami A, et al. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest 2003;112:415–422.PubMedCrossRefGoogle Scholar
  15. 15.
    Furlan R, Brambilla E, Sanvito F, et al. Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice. Brain 2003;126:285–291.PubMedCrossRefGoogle Scholar
  16. 16.
    Iwanaga T. The involvement of macrophages and lymphocytes in the apoptosis of enterocytes. Arch Histol Cytol 1995;58:151–159.PubMedGoogle Scholar
  17. 17.
    McLaurin J, Cecal R, Kierstead ME, et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 2002;8:1263–1269.PubMedCrossRefGoogle Scholar
  18. 18.
    Frenkel D, Katz O, Solomon B. Immunization against Alzheimer's beta-amyloid plaques via EFRH phage administration. Proc Natl Acad Sci USA 2000;97:11455–11459.PubMedCrossRefGoogle Scholar
  19. 19.
    Bard F, Barbour R, Cannon C, et al. Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer’s disease-like neuropathology. Proc Natl Acad Sci U S A 2003;100:2023–2028.PubMedCrossRefGoogle Scholar
  20. 20.
    DeMattos RB, Bales KR, Cummins DJ, et al. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A 2001;98:8850–8855.PubMedCrossRefGoogle Scholar
  21. 21.
    DeMattos RB, Bales KR, Cummins DJ, et al. Brain to plasma amyloid-β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer’s disease. Science 2002;295:2264–2267.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Takeshi Tabira
    • 1
  • Hideo Hara
  1. 1.National Institute for Longevity Sciences NCGGMorioka, Obu CityJapan

Personalised recommendations